Abilify Maintena

Abilify Maintena®

(aripiprazole)

19 Aug, 2024

Expert opinion: dopamine partial agonists and long-acting injectables

Professor John Kane provides his expert opinion on treating patients with schizophrenia, with dopamine partial agonists and long-acting injectables (LAIs).

19 Aug, 2024

Could a dopamine partial agonist benefit your patients with schizophrenia?

19 Aug, 2024

Could your patients with schizophrenia benefit from a long-acting injectable?

Box

Body

Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
text

Body

Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

Abilify Maintena PI

Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Contributor

Professor John Kane

Senior Vice President of Behavioural Health Services, Northwell Health and Chair of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Abilify Maintena

Abilify Maintena®

Expert opinion: dopamine partial agonists and long-acting injectables

Could a dopamine partial agonist benefit your patients with schizophrenia?

Could your patients with schizophrenia benefit from a long-acting injectable?

GO TO

Contributor

BROUGHT TO YOU BY

LUNDBECK AUSTRALIA PRODUCTS

subscribe newsletter